Liquidia Technologies, Inc.
Clinical trials sponsored by Liquidia Technologies, Inc., explained in plain language.
-
New inhaled powder shows promise for Lung-Related high blood pressure
Disease control OngoingThis study tests the safety of an inhaled dry powder drug called LIQ861 (treprostinil) in 80 adults with pulmonary hypertension (high blood pressure in the lungs) linked to lung disease. Participants receive the drug through an inhaler, and researchers monitor for side effects. T…
Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated May 17, 2026 14:09 UTC
-
New Twice-Daily inhaler shows promise for lung hypertension patients
Disease control OngoingThis study tests a new inhaled medicine called L606 for people with high blood pressure in the lungs (pulmonary arterial hypertension or related to lung disease). The goal is to see if switching to or starting L606, taken twice daily, is safe and tolerable. About 28 adults aged 1…
Phase: PHASE3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated May 17, 2026 14:08 UTC